Efpeglenatide

Drug Profile

Efpeglenatide

Alternative Names: HM-11260C; LAPS-Exd4; LAPS-Exendin; LAPS-exendin 4 analogue; LAPS-Exendin4; LAPSCA-Exendin4

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Peptides; Polyethylene glycols
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 05 Nov 2015 Efpeglenatide licensed to Sanofi worldwide for the treatment of Type-2 diabetes mellitus
  • 25 Aug 2015 Efpeglenatide is still in phase II trials for Type-2 diabetes mellitus in the USA (SC, Injection, Once-monthly)
  • 01 Feb 2015 Hanmi Pharmaceutical completes a phase I trial in Obesity in Hungary, Germany and Netherlands (NCT02075281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top